JP2023513487A5 - - Google Patents

Info

Publication number
JP2023513487A5
JP2023513487A5 JP2022547042A JP2022547042A JP2023513487A5 JP 2023513487 A5 JP2023513487 A5 JP 2023513487A5 JP 2022547042 A JP2022547042 A JP 2022547042A JP 2022547042 A JP2022547042 A JP 2022547042A JP 2023513487 A5 JP2023513487 A5 JP 2023513487A5
Authority
JP
Japan
Prior art keywords
patient
seq
raav
human
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022547042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513487A (ja
JP7874545B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/015988 external-priority patent/WO2021155337A1/en
Publication of JP2023513487A publication Critical patent/JP2023513487A/ja
Publication of JP2023513487A5 publication Critical patent/JP2023513487A5/ja
Priority to JP2026068599A priority Critical patent/JP2026123078A/ja
Application granted granted Critical
Publication of JP7874545B2 publication Critical patent/JP7874545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022547042A 2020-02-02 2021-02-01 Gm1ガングリオシドーシスを治療するのに有用な組成物 Active JP7874545B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026068599A JP2026123078A (ja) 2020-02-02 2026-04-17 Gm1ガングリオシドーシスを治療するのに有用な組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062969142P 2020-02-02 2020-02-02
US62/969,142 2020-02-02
US202063007297P 2020-04-08 2020-04-08
US63/007,297 2020-04-08
US202063063119P 2020-08-07 2020-08-07
US63/063,119 2020-08-07
PCT/US2021/015988 WO2021155337A1 (en) 2020-02-02 2021-02-01 Compositions useful for treating gm1 gangliosidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026068599A Division JP2026123078A (ja) 2020-02-02 2026-04-17 Gm1ガングリオシドーシスを治療するのに有用な組成物

Publications (3)

Publication Number Publication Date
JP2023513487A JP2023513487A (ja) 2023-03-31
JP2023513487A5 true JP2023513487A5 (cg-RX-API-DMAC7.html) 2024-02-08
JP7874545B2 JP7874545B2 (ja) 2026-06-16

Family

ID=74867612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022547042A Active JP7874545B2 (ja) 2020-02-02 2021-02-01 Gm1ガングリオシドーシスを治療するのに有用な組成物
JP2026068599A Pending JP2026123078A (ja) 2020-02-02 2026-04-17 Gm1ガングリオシドーシスを治療するのに有用な組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026068599A Pending JP2026123078A (ja) 2020-02-02 2026-04-17 Gm1ガングリオシドーシスを治療するのに有用な組成物

Country Status (12)

Country Link
US (1) US20230190966A1 (cg-RX-API-DMAC7.html)
EP (1) EP4096721A1 (cg-RX-API-DMAC7.html)
JP (2) JP7874545B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220145838A (cg-RX-API-DMAC7.html)
CN (1) CN115867323A (cg-RX-API-DMAC7.html)
AU (1) AU2021213826A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022013914A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165057A1 (cg-RX-API-DMAC7.html)
IL (1) IL294924A (cg-RX-API-DMAC7.html)
MX (1) MX2022009462A (cg-RX-API-DMAC7.html)
TW (1) TWI905145B (cg-RX-API-DMAC7.html)
WO (1) WO2021155337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860659A1 (en) 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis
WO2023147351A1 (en) * 2022-01-25 2023-08-03 Regents Of The University Of Minnesota Crispr-mediated human genome editing with vectors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
WO2016049230A1 (en) 2014-09-24 2016-03-31 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
MA43968A (fr) * 2016-02-03 2018-12-12 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type i
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
WO2019222314A1 (en) * 2018-05-15 2019-11-21 University Of Massachusetts Raav vectors encoding of lysosomal beta-galactorsidase (glb1) and cathepsin a
EP3860659A1 (en) * 2018-10-01 2021-08-11 The Trustees of the University of Pennsylvania Compositions useful for treating gm1 gangliosidosis

Similar Documents

Publication Publication Date Title
JP2021523198A5 (cg-RX-API-DMAC7.html)
JP2022512589A5 (cg-RX-API-DMAC7.html)
JP2005021149A (ja) アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
JP2022523766A5 (cg-RX-API-DMAC7.html)
JP2024517143A5 (cg-RX-API-DMAC7.html)
JP2020526514A5 (cg-RX-API-DMAC7.html)
JP2024515459A5 (cg-RX-API-DMAC7.html)
JP7413629B2 (ja) Igf-1異型体を発現させるdnaコンストラクトを用いた神経病症の治療
WO2009052737A1 (en) Medicament for preventing and controlling alzheimer's disease
JP2014506787A (ja) シアル酸産生を増加させて、シアル酸に関連した病状を治療する方法および組成物
JP2025506681A5 (cg-RX-API-DMAC7.html)
JP2022060514A (ja) ガバペンチノイドからの干渉が減少し、hgf異型体を発現するdnaコンストラクトを用いる神経病症の治療
JP2022537555A5 (cg-RX-API-DMAC7.html)
JP2022525848A5 (cg-RX-API-DMAC7.html)
JP2025508841A5 (cg-RX-API-DMAC7.html)
WO2022255906A1 (en) Drug for genetic and gene-cell-based therapy
TW202140791A (zh) 治療苯酮尿症之方法
JP2022550954A5 (cg-RX-API-DMAC7.html)
US12630840B2 (en) One-step gene therapy for Duchenne muscular dystrophy via gene replacement and anti-inflammation
EP3570896B1 (en) Compositions for reducing sarcolipin expression and preventing and treating muscular dystrophy and cardiomyopathy and methods of use
JP2023526311A5 (cg-RX-API-DMAC7.html)
KR20220084052A (ko) 치료제로서의 gne
JP2022518354A5 (cg-RX-API-DMAC7.html)
CN118146318B (zh) 一种腺相关病毒衣壳蛋白及其用途
CN116590342A (zh) 一种aav载体及其应用